title: SDZ GLC 756, a novel octahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D1 and D2 receptors.
abstract: SDZ GLC-756, a novel octahydrobenzo[g]quinoline derivative, is equipotent in displacing [3H]SCH23390 from dopamine D1 receptors and [3H]205-501 from dopamine D2 receptor binding sites. It blocks dopamine sensitive adenylate cyclase with the same potency as SCH23390, indicating antagonist properties at dopamine D1 receptors. On the other hand, SDZ GLC 756 inhibits electrically evoked acetylcholine release from rat striatal slices with the same potency as the selective dopamine D2 receptor agonist bromocriptine. This effect is blocked by spiperone suggesting that it is mediated by dopamine D2 receptor activation. The opposing action of SDZ GLC 756 on dopamine D1 and D2 receptors is also evident in vivo. SDZ GLC 756, like SCH23390, blocks apomorphine-induced rearing in mice. On the other hand, it inhibits prolactin secretion and produces circling in unilateral 6-OHDA-lesioned rats, which is compatible with stimulant properties at dopamine D2 receptors. This drug might be a new tool to study linkage between dopamine D1 and D2 receptors.
authors.affiliation: Preclinical Research, Sandoz Pharma Ltd., Basle, Switzerland.
authors.forename: R
authors.initials: R
authors.lastname: Markstein
authors.forename: P
authors.initials: P
authors.lastname: Gull
authors.forename: C
authors.initials: C
authors.lastname: Rüdeberg
authors.forename: S
authors.initials: S
authors.lastname: Urwyler
authors.forename: A L
authors.initials: AL
authors.lastname: Jaton
authors.forename: H O
authors.initials: HO
authors.lastname: Kalkman
authors.forename: A K
authors.initials: AK
authors.lastname: Dixon
authors.forename: D
authors.initials: D
authors.lastname: Hoyer
mesh_terms: D000109:Acetylcholine / Q000378:metabolism; D000262:Adenylyl Cyclases / Q000096:biosynthesis; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D002417:Cattle; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000494:pharmacology; D015259:Dopamine Agents / Q000494:pharmacology*; D018491:Dopamine Agonists / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D017072:Neostriatum / Q000187:drug effects / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D016627:Oxidopamine / Q000494:pharmacology; D011388:Prolactin / Q000378:metabolism; D011804:Quinolines / Q000494:pharmacology*; D011869:Radioligand Assay; D051381:Rats; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors*; D017448:Receptors, Dopamine D2 / Q000819:agonists*; D012701:Serotonin / Q000378:metabolism; D013239:Stereotyped Behavior / Q000187:drug effects; D013565:Sympatholytics / Q000494:pharmacology
chemical_list: D015259:Dopamine Agents; D018491:Dopamine Agonists; D011804:Quinolines; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; C102871:SDZ GLC 756; D013565:Sympatholytics; D012701:Serotonin; D016627:Oxidopamine; D011388:Prolactin; D000262:Adenylyl Cyclases; D001058:Apomorphine; D000109:Acetylcholine; D004298:Dopamine; D009638:Norepinephrine